
Sign up to save your podcasts
Or


In this edition, FDA votes to support approval of ALS therapy; partnership offers military veterans access to psychedelics; epidural steroid injections as alternate pain management options and more.
Read the full coverage here:
FDA advisory committee votes to support approval of ALS therapy
Partnership offers military veterans access to psychedelics at home, abroad
Epidural steroid injection an alternate pain management option
Ketamine may be effective in treating children with ADNP syndrome
FDA accepts new drug application for Rett syndrome treatment
References:
Christo PJ. Landscape of wonders: Injections, nerve blocks, pumps and neuromodulation. Presented at: PAINWeek; Las Vegas; Sept. 9-12, 2022.
Kolevzon A, et al. HGG Adv. 2022;doi:10.1016/j.xhgg.2022.100138.
Press Release
Press Release
Press Release
In this edition, new cannabinoids hold promise for medical applications; Theranica secures $45 million for migraine treatment device and more.
Read the full coverage here:
Newly discovered cannabinoids hold promise for medical, pain applications
Theranica secures $45 million to expand wearable migraine treatment device in US
Implantable loop recorder screening for AF not linked to stroke reduction risk
Survey shows OTC pain relievers remain 'common, valuable'
Amneal submits new drug application for extended-release Parkinson's treatment
References:
Diederichsen SZ et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3031.
Guglieri M et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2480.
Jacknin J. How green is my valley: Newly discovered cannabinoids and their possible medical uses. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022.
Press Release
Press Release
In this edition, germline testing 'should be considered' for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more.
Read the full coverage here:
Germline testing 'should be considered' for all patients with lung cancer, data suggest
Phase 3 trial of canakinumab for non-small cell lung cancer misses endpoint
Sexual dysfunction common among women with lung cancer
Younger patients with lung cancer more likely to have advanced disease at diagnosis
Sotorasib extends PFS in lung cancer subset
References:
Florez N, et al. Abstract MA14. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Potter A, et al. Abstract OA05. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Press Release
Press Release
Sorscher S, et al. Abstract 388570. Presented at: ASCO Plenary Series (virtual); Aug. 16, 2022.
In this episode, VTE rate with abemaciclib (uh-bem-uh-cy-clib) higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant (ee-las-cess-trant) for metastatic disease; and more.
Read the full coverage here:
VTE rate with abemaciclib higher in real-world setting among patients with breast cancer
Enhertu extends progression-free survival in breast cancer subgroup, topline data show
FDA grants priority review to elacestrant for metastatic breast cancer
Lack of financial comfort linked to weight gain among young breast cancer survivors
Hispanic ethnicity often not reported in breast cancer studies
References:
Bazan JG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.3527.
Press Release
Press Release
Sella T, et al. Cancer. 2022;doi:10.1002/cncr.34342.
Watson NW, et al. Cancer. 2022.doi:10.1002/cncr.34367.
In this edition, blood-based concussion diagnostic tool gets patent; examining the brain's electrical signals may be key to treating epilepsy, schizophrenia; machine-learning model may predict best antiseizure medications and more.
Read the full coverage here:
Neurolytixs secures US patent for blood-based concussion diagnostic tool
Examination of brain's electrical signals may be key to treating epilepsy, schizophrenia
Machine-learning model may predict which antiseizure medications work best
Rafa receives FDA approval for autoinjector to treat status epilepticus in adults
Aptinyx completes enrollment of phase 2 trial for oral cognitive impairment treatment
References:
Hakeem H, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2514.
Press Release
Press Release
Press Release
Press Release
In this edition, BMI is associated with dementia in women and linked with disease in men; Healthy diet, physical activity are linked to lower mortality in adults with PD; mild TBI and CT scans and more.
Read the full coverage here:
High BMI negatively associated with dementia in women, low BMI linked with disease in men
Healthy diet, physical activity linked to lower mortality rate in adults with PD
Patients with mild TBI, negative CT scan should be evaluated 2 weeks after injury
FDA approves spinal cord stimulation system for broad treatment of chronic pain
Artificial intelligence model detects Parkinson's disease via nocturnal breathing signals
References:
Jacob L, et al. J Alzheimers Dis. 2022;doi:10.3233/JAD-220147.
Madhok DY, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.23245.
Press Release
Yang Y, et al. Nat Med. 2022;doi:10.1038/s41591-022-01932-x.
Zhang X et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.27738.
In this edition, macular retinal nerve fiber layer thickness linked with cognitive decline; FDA approves Lucentis biosimilar; advanced visual field loss risk higher after glaucoma diagnosis in Black patients; and more.
Association found between macular retinal nerve fiber layer thickness, cognitive decline
FDA approves Cimerli as interchangeable biosimilar to Lucentis
Black patients have higher risk for advanced visual field loss after glaucoma diagnosis
iStent infinite cleared by FDA
Alcon to acquire Aerie Pharmaceuticals
References:
Kang JH, et al. Transl Vis Sci Technol. 2022;doi:10.1167/tvst.11.7.21.
Kim HM, et al. JAMA Ophthalmol. 2022;doi:10.1001/jamaophthalmol.2022.1563.
Press Release
Press Release
Press Release
In this edition, leisure activities may lower risk for Alzheimer's disease and dementia; most common long COVID symptoms include fatigue and headache; 'life-changing' app-based digital therapeutic for tinnitus and more.
Read the full coverage here:
Leisure activities may lower risk for Alzheimer's disease, dementia
Fatigue, headache most common long COVID symptoms
Personalized, app-based digital therapeutic for tinnitus 'life-changing'
NIH to fund development, testing of robots to aid in Alzheimer's disease care
AI algorithm detects brain abnormalities, could help treat epilepsy
References:
Chen AK, et al. Brain Behav Immun. 2022;doi:10.1016/j.bbih.2022.100491
Press Release
Searchfield GD, et al. Front Neurol. 2022;doi:10.3389/fneur.2022.958730
Spitzer H, et al. Brain. 2022;doi:10.1093/brain/awac224
Su S, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200929
In this edition, light stimulation may help delay Alzheimer's progression; sleep EEGs may predict future disease and mortality; updated data on the prevalence of tinnitus and more.
Read the full coverage here:
Light stimulation may help delay AD progression, more research needed in older adults
Sleep EEGs may predict future disease, mortality
Tinnitus affects more than 740 million adults globally
Gut-based neurotoxin triggers inflammation associated with Alzheimer's disease
CSF biomarkers support AD diagnosis in nearly 90% of clinical cases
References:
Agüero P, et al. CSF Alzheimer's biomarkers in clinical practice. Presented at: Alzheimer's Association International Conference; July 31-Aug. 4; San Diego.
Beckers E, et al. Characterization of pupillary responses to alternating blue and orange light exposures in a fMRI protocol. Presented at: Alzheimer's Association International Conference; July 31-Aug. 4; San Diego.
Jarach CM, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2189.
Pogue AI, et al. Front Neurol. 2022;doi:10.3389/fneur.2022.900.048
Sun H, et al. Predicting incident outcomes from the microstructure of sleep. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C.
In this edition, lung cancer risk is high among smokers for whom screening is not recommended; the role of circulating tumor DNA in lung cancer detection and treatment is 'exciting' for field; a subset of patients with lung cancer have poor response to COVID-19 vaccines, and more.
Read the full coverage here:
Lung cancer risk high among smokers for whom screening is not recommended
Role of circulating tumor DNA in lung cancer detection, treatment 'exciting' for field
Subset of patients with lung cancer have poor response to COVID-19 vaccines
Low area-level income, education linked to higher odds of late-stage lung cancer diagnosis
Phase 3 trial of Onivyde for small cell lung cancer misses endpoint
References:
Faselis C, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2952.
Gupta A, et al. Cancer. 2022;doi:10.1002/cncr.34327.
Healio Interview
Press Release
Valanparambil RM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02986.
From the publisher's feed